MARKET

TARA

TARA

Protara Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.140
0.000
0.00%
Closed 16:00 05/24 EDT
OPEN
3.210
PREV CLOSE
3.140
HIGH
3.379
LOW
3.110
VOLUME
43.88K
TURNOVER
101.10K
52 WEEK HIGH
11.10
52 WEEK LOW
2.720
MARKET CAP
35.33M
P/E (TTM)
-0.7926
1D
5D
1M
3M
1Y
5Y
Protara Therapeutics to Present at the H.C. Wainwright Global Investment Conference
NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainw...
GlobeNewswire · 05/17 12:00
Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Simply Wall St. · 05/17 11:32
Protara Therapeutics Shares Retrospective Analysis Of OK-432 In Rare Lymphatic Malformations
Benzinga · 05/12 15:11
BRIEF-Protara Therapeutics Presents Results From Analysis Of Studies Of OK-432 In Patients With Lymphatic Malformations
reuters.com · 05/12 12:24
Protara Therapeutics Presents Results from Retrospective Analysis of Randomized and Open-Label Studies Evaluating the Safety and Efficacy of OK-432 in Patients with Lymphatic Malformations
Data showed OK-432 was clinically successful in treating lymphatic malformations and support a favorable safety profileNEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative ...
GlobeNewswire · 05/12 12:00
--Oppenheimer Adjusts Protara Therapeutics Price Target to $26 From $32, Maintains Outperform Rating
MT Newswires · 05/11 11:00
--HC Wainwright Lowers Protara Therapeutics Price Target to $30 From $40, Buy Rating Kept
MT Newswires · 05/09 11:26
ArTara Therapeutics GAAP EPS of -$0.96 misses by $0.06
ArTara Therapeutics press release (NASDAQ:TARA): Q1 GAAP EPS of -$0.96 misses by $0.06. As of March 31, 2022, cash, cash equivalents and restricted cash were $118.5 million. The Company expects
Seekingalpha · 05/05 13:04
More
No Data
Learn about the latest financial forecast of TARA. Analyze the recent business situations of Protara Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average TARA stock price target is 34.50 with a high estimate of 50.00 and a low estimate of 26.00.
High50.00
Average34.50
Low26.00
Current 3.140
EPS
Actual
Estimate
-0.91-0.68-0.46-0.23
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 48
Institutional Holdings: 9.82M
% Owned: 87.24%
Shares Outstanding: 11.25M
TypeInstitutionsShares
Increased
8
57.50K
New
3
46.83K
Decreased
17
437.50K
Sold Out
7
49.27K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.04%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Non-Executive Chairman/Independent Director
Luke Beshar
President/Chief Executive Officer/Director
Jesse Shefferman
Chief Financial Officer
Blaine Davis
Chief Operating Officer/Chief Scientific Officer
Jacqueline Zummo
Senior Vice President/Director of Investor Relations/IR Contact Officer
Justine O'Malley
Other
Jathin Bandari
Independent Director
Barry Flannelly
Independent Director
Roger Garceau
Independent Director
Jane Huang
Independent Director
Richard Levy
Independent Director
Gregory Sargen
Independent Director
Cynthia Smith
Independent Director
Michael Solomon
No Data
No Data
About TARA
Protara Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying therapies for the treatment of cancer and rare diseases. The Company's pipeline includes TARA-002, IV Choline Chloride and Vonapanitase. The Company's lead product pipeline is TARA 002 for the treatment of non-muscle invasive bladder cancer (NMIBC) and Lymphatic Malformations (LMs). TARA 002 is a cellular therapy based on OK-432, also known as Picibanil, which is derived from a genetically distinct strain of Streptococcus Pyogenes. IV choline chloride is intravenous (IV) substrate replacement therapy for patients with choline deficiency who exhibit symptoms of liver impairment. IV Choline Chloride is being developed for the treatment of Intestinal Failure Associated Liver Disease (IFALD). Vonapanitase is a recombinant human elastase that are developing for the improvement of vascular access outcomes in patients with chronic kidney disease.

Webull offers kinds of Protara Therapeutics Inc stock information, including NASDAQ:TARA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TARA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TARA stock methods without spending real money on the virtual paper trading platform.